Tempsens Instruments (India) Ltd₹305101.7%Hy Tech Engineers Ltd₹4279.3%Kwick Forensic Solutions Ltd₹6673.3%Farm Peace Ltd₹4271.2%Poojaa Precision Engg Ltd₹19364.1%ESDS Software Solution Ltd₹21550.1%Shanti Inorganics Ltd₹3947.0%Ashutosh Fibre Ltd₹4245.7%Behari Lal Engineering Ltd₹12744.6%Technocrats Plasma Systems Ltd₹5642.4%Lumino Industries Ltd₹3441.5%Shiprocket Ltd₹3839.2%

Symbiotec Pharmalab Ltd IPO

Listed Mainboard BSE, NSE Bookbuilding IPO
Min Investment
₹14,820
15 shares · 1 lot

Symbiotec Pharmalab Ltd IPO was priced at ₹938–₹988 per share with an issue size of ₹1,757 crore. The IPO opened on Aug 24, 2026 and closed on Aug 27, 2026, with a lot size of 15 shares and a minimum investment of ₹14,820.

Open
24 Aug
Close
27 Aug
Allotment
28 Aug
Refund
31 Aug
Listing
01 Sep

Market Sentiment

Grey Market Premium

Full history →
+₹205.00 +20.8%
Est. listing: ₹1,193
Updated 31 Aug 2026
GMP is an informal, unregulated grey-market figure. It is not a guaranteed listing price and can move sharply during the bidding window.

Live Subscription

All IPOs →

Subscription data isn't available yet — it appears once bidding opens.

IPO Details

Price Band ₹938.00 - ₹988.00 per share
Lot Size15 shares
Min Investment₹14,820
Total Issue Size ₹1757.00 crore
Shares Offered1,77,86,442
Issue Structure Fresh Issue + Offer for Sale
Issue TypeBookbuilding IPO
Lead Manager(s)JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd.
RegistrarMUFG Intime India Pvt.Ltd.
Listing AtBSE, NSE

Quick Profit Calculator

Issue price ₹988 · lot size 15 shares · estimated listing price ₹1,193 (GMP +₹205)

Category Lots Shares Investment Value at listing Profit
Retail (Min) 1 15 ₹14,820 ₹17,895 +₹3,075
Retail (Max) 13 195 ₹1,92,660 ₹2,32,635 +₹39,975
S-HNI (Min) 14 210 ₹2,07,480 ₹2,50,530 +₹43,050
S-HNI (UPI limit) 33 495 ₹4,89,060 ₹5,90,535 +₹1,01,475
S-HNI (Max) 67 1,005 ₹9,92,940 ₹11,98,965 +₹2,06,025
B-HNI (Min) 68 1,020 ₹10,07,760 ₹12,16,860 +₹2,09,100
Estimated from the grey market premium, an informal and unregulated figure that moves sharply and frequently differs from the eventual listing price. Not a forecast. Assumes full allotment, which is rarely guaranteed when an issue is oversubscribed.

Financial Analysis

EPS
₹17.82
P/E (Post)
56.81 x
RoNW
9.48%
RoCE
11.56%
Net Worth
₹1158.64 Cr
MetricLatest Reported
Total Income₹872.26 Cr
Profit After Tax₹109.90 Cr
Net Worth₹1158.64 Cr

Promoters & Holding

Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani

Promoter Holding (Pre-Issue)61681496%
Promoter Holding (Post-Issue)63202757%

Strengths & Risks

Strengths

  • Global leadership in corticosteroid and steroidal hormone APIs.
  • Long-standing relationships with domestic and international customers.
  • Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
  • Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
  • Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.

Risks & Concerns

  • Regulatory risks associated with pharmaceutical manufacturing.
  • Market competition from other pharmaceutical companies.
  • Dependence on a limited number of customers for a significant portion of revenue.
  • Potential fluctuations in raw material prices affecting profitability.
Summarised from the company's own DRHP/RHP disclosures. Informational only, not investment advice — always read the full prospectus before applying.

Company Information

Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.

Evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform.

Founded2002
HeadquartersIndore, Madhya Pradesh
IndustryPharmaceuticals
Websitehttps://www.symbiotec.com/

Objects of the Issue

  • Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
  • General corporate purposes

Registrar & Allotment

RegistrarMUFG Intime India Pvt.Ltd.
Phone022-49186000
Email[email protected]

Resources & Documents

Frequently Asked Questions

11 answers about Symbiotec Pharmalab Ltd IPO — dates, pricing, allotment and listing.

Symbiotec Pharmalab Ltd IPO is a bookbuilding ipo of ₹1,757 crore. The issue was priced at ₹938–₹988 per share, with a lot size of 15 shares. Bidding ran from Mon, 24 Aug 2026 to Thu, 27 Aug 2026, with shares listed on BSE and NSE.

The price band was ₹938–₹988 per share.

One lot was 15 shares. Bids had to be placed in multiples of 15.

A retail investor needed at least ₹14,820 – one lot of 15 shares at ₹988, the upper end of the price band.

Symbiotec Pharmalab Ltd IPO opened on Mon, 24 Aug 2026 and closed on Thu, 27 Aug 2026.

Allotment was finalised on Fri, 28 Aug 2026.

Symbiotec Pharmalab Ltd shares were listed on Tue, 01 Sep 2026 on BSE and NSE.

The company intended to use the net proceeds towards prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company and general corporate purposes.

JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. and Nomura Financial Advisory & Securities (India) Pvt.Ltd. are the book running lead managers. MUFG Intime India Pvt.Ltd is the registrar to the issue.

Category-wise demand from retail, NII and QIB bidders is on the Symbiotec Pharmalab Ltd IPO subscription page, and on the BSE and NSE websites.

From Fri, 28 Aug 2026, check the Symbiotec Pharmalab Ltd IPO allotment status using your PAN, application number or DP ID – also available on the registrar's website.